On August 2, 2021, Justin Thacker notified Design Therapeutics, Inc. of his intention to resign as the company’s VP, Finance and from his position as the company’s principal accounting officer, effective August 13, 2021, to pursue another opportunity. Effective as of August 13, 2021, Dawn Giangiulio, the Company’s Controller, will become the Company’s interim principal accounting officer for purposes of the Securities Exchange Act of 1934, as amended. Ms. Giangiulio joined the Company as Controller in April 2020. Ms. Giangiulio also currently serves as Controller of ARS Pharmaceuticals, Inc. on a part-time basis and has resigned from ARS Pharmaceuticals, Inc. effective as of September 3, 2021.